Published in Hum Pathol on August 01, 1996
Role of microglia in central nervous system infections. Clin Microbiol Rev (2004) 2.69
Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun (2008) 2.15
Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am J Pathol (2004) 1.87
Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol (2005) 1.80
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis (2014) 1.68
Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest (2010) 1.67
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
Human neutrophil-mediated nonoxidative antifungal activity against Cryptococcus neoformans. Infect Immun (2000) 1.38
Cryptococcal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am J Pathol (2009) 1.38
IL-4/IL-13-dependent alternative activation of macrophages but not microglial cells is associated with uncontrolled cerebral cryptococcosis. Am J Pathol (2009) 1.27
Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog (2006) 1.27
Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice. Infect Immun (1999) 1.19
Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS One (2008) 1.14
Management of Cryptococcus gattii meningoencephalitis. Lancet Infect Dis (2014) 1.12
Cytokine profiles of AIDS patients are similar to those of mice with disseminated Cryptococcus neoformans infection. Infect Immun (1999) 1.08
Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. J Clin Invest (2014) 1.08
Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS (2010) 1.07
Requirement for CD4(+) T lymphocytes in host resistance against Cryptococcus neoformans in the central nervous system of immunized mice. Infect Immun (2000) 1.04
Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitis. Infect Immun (2005) 1.01
New Insights into HIV/AIDS-Associated Cryptococcosis. ISRN AIDS (2013) 0.98
Blood-brain barrier invasion by Cryptococcus neoformans is enhanced by functional interactions with plasmin. Microbiology (2011) 0.97
Molecular mechanisms of cryptococcal meningitis. Virulence (2012) 0.97
Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob Agents Chemother (1997) 0.94
Loss of allergen 1 confers a hypervirulent phenotype that resembles mucoid switch variants of Cryptococcus neoformans. Infect Immun (2008) 0.92
Fcgamma receptor I- and III-mediated macrophage inflammatory protein 1alpha induction in primary human and murine microglia. Infect Immun (2002) 0.91
Phenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host response. Infect Immun (2008) 0.90
Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol (2012) 0.90
Difficulty diagnosing chronic cryptococcal meningitis in idiopathic CD4+ lymphocytopenia. Neurol Sci (2011) 0.89
Cryptococcus neoformans induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta in human microglia: role of specific antibody and soluble capsular polysaccharide. Infect Immun (2001) 0.87
An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults. J Clin Exp Neuropsychol (2008) 0.87
Massive cerebral edema resulting in brain death as a complication of Cryptococcus neoformans meningitis. J Community Hosp Intern Med Perspect (2015) 0.87
A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. J Infect Dis (2016) 0.84
Effect of cytokines on anticryptococcal activity of human microglial cells. Clin Diagn Lab Immunol (1998) 0.84
Dual roles of CD40 on microbial containment and the development of immunopathology in response to persistent fungal infection in the lung. Am J Pathol (2010) 0.81
Fighting the Monster: Applying the Host Damage Framework to Human Central Nervous System Infections. MBio (2016) 0.81
Diffusion tensor imaging study of white matter damage in chronic meningitis. PLoS One (2014) 0.79
A fatal case of AIDS-defining meningoencephalitis by C. neoformans, sensitive to antifungal therapy. Eur J Med Res (2010) 0.78
Cryptococcal meningoencephalitis in HIV/AIDS: when to start antiretroviral therapy? Ann Clin Microbiol Antimicrob (2017) 0.75
Disseminated cryptococcosis in a patient with HIV/AIDS at a teaching hospital in Ghana. SAGE Open Med Case Rep (2015) 0.75
Cysteinyl leukotrienes as novel host factors facilitating Cryptococcus neoformans penetration into the brain. Cell Microbiol (2016) 0.75
Antibody responses to Cryptococcus neoformans in Indian patients with cryptococcosis. Med Mycol (2008) 0.75
Subarachnoid small vein occlusion due to inflammatory fibrosis-a possible mechanism for cerebellar infarction in cryptococcal meningoencephalitis: a case report. BMC Neurol (2017) 0.75
Role of microglia in fungal infections of the central nervous system. Virulence (2016) 0.75
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology (1996) 12.33
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol (1996) 4.10
Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain (2007) 3.82
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
Urease as a virulence factor in experimental cryptococcosis. Infect Immun (2000) 3.53
A neuronal antigen in the brains of Alzheimer patients. Science (1986) 3.49
Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun (1995) 3.43
Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun (2000) 3.42
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol (1999) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Intracellular parasitism of macrophages by Cryptococcus neoformans. Trends Microbiol (2001) 3.34
Persistence of initial infection in recurrent Cryptococcus neoformans meningitis. Lancet (1993) 3.34
Protective murine monoclonal antibodies to Cryptococcus neoformans. Infect Immun (1992) 3.21
Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol (2001) 3.02
Estimation of the prevalence of cryptococcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis (1994) 2.87
DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology (2007) 2.86
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol (1997) 2.60
Cytokine production by human fetal microglia and astrocytes. Differential induction by lipopolysaccharide and IL-1 beta. J Immunol (1993) 2.46
Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology (2008) 2.45
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect Immun (1994) 2.41
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J Immunol (1997) 2.25
Cockayne syndrome and xeroderma pigmentosum. Neurology (2000) 2.24
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Melanin, melanin "ghosts," and melanin composition in Cryptococcus neoformans. Infect Immun (1996) 2.15
A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. Proc Natl Acad Sci U S A (1998) 2.13
DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology (2004) 2.12
Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect Immun (1998) 2.12
Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med (1995) 2.11
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect Immun (1995) 2.09
Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med (1993) 2.09
Dynamic changes in the morphology of Cryptococcus neoformans during murine pulmonary infection. Microbiology (2001) 2.08
Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun (1994) 2.07
Abnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype. Neurology (2008) 2.01
Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. Antimicrob Agents Chemother (1994) 2.00
Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci (1997) 2.00
Pathology and biology of the Lewy body. J Neuropathol Exp Neurol (1993) 1.99
Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology (2003) 1.97
Recognition of tau epitopes by anti-neurofilament antibodies that bind to Alzheimer neurofibrillary tangles. Proc Natl Acad Sci U S A (1987) 1.96
TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. Neurology (2010) 1.93
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother (1997) 1.89
Medulloblastoma with glial and rhabdomyoblastic differentiation. A myoglobin and glial fibrillary acidic protein immunohistochemical and ultrastructural study. J Neuropathol Exp Neurol (1983) 1.88
Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology (2004) 1.86
Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc Natl Acad Sci U S A (1993) 1.86
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
Monoclonal antibodies to Alzheimer neurofibrillary tangles. 1. Identification of polypeptides. Am J Pathol (1985) 1.84
Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun (1994) 1.83
Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated immunity against Mycobacterium tuberculosis. Clin Microbiol Rev (1998) 1.82
Parkinsonism, Lrrk2 G2019S, and tau neuropathology. Neurology (2006) 1.81
Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol (2000) 1.79
Phenotypic variability of Gerstmann-Sträussler-Scheinker disease is associated with prion protein heterogeneity. J Neuropathol Exp Neurol (1998) 1.79
Tissue localization of Cryptococcus neoformans glucuronoxylomannan in the presence and absence of specific antibody. Infect Immun (1995) 1.79
Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect Immun (2000) 1.79
Monoclonal antibodies to Alzheimer neurofibrillary tangles. 2. Demonstration of a common antigenic determinant between ANT and neurofibrillary degeneration in progressive supranuclear palsy. Am J Pathol (1985) 1.77
Monoclonal antibodies to surface antigens of Mycobacterium tuberculosis and their use in a modified enzyme-linked immunosorbent spot assay for detection of mycobacteria. J Clin Microbiol (1996) 1.76
T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc Natl Acad Sci U S A (1997) 1.72
Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans. Genes Dev (2001) 1.72
Imaging correlates of pathology in corticobasal syndrome. Neurology (2010) 1.71
Variation in the structure of glucuronoxylomannan in isolates from patients with recurrent cryptococcal meningitis. Infect Immun (1995) 1.70
Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol (1993) 1.70
Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology (1999) 1.70
Cellular charge of Cryptococcus neoformans: contributions from the capsular polysaccharide, melanin, and monoclonal antibody binding. Infect Immun (1997) 1.69
Isotype switching from IgG3 to IgG1 converts a nonprotective murine antibody to Cryptococcus neoformans into a protective antibody. J Immunol (1995) 1.67
Enhancement of HIV-1 infection by the capsular polysaccharide of Cryptococcus neoformans. Lancet (1992) 1.67
Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol (1990) 1.67
Alzheimer's neurofibrillary tangles contain unique epitopes and epitopes in common with the heat-stable microtubule associated proteins tau and MAP2. Am J Pathol (1987) 1.66
Decreased susceptibility of melanized Cryptococcus neoformans to UV light. Appl Environ Microbiol (1994) 1.65
Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun (2001) 1.64
Organ-dependent variation of capsule thickness in Cryptococcus neoformans during experimental murine infection. Infect Immun (1998) 1.63
Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun (1999) 1.60
Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med (1997) 1.60
Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol (1996) 1.60
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies. Neurology (2011) 1.59
Melanization of Cryptococcus neoformans in murine infection. Mol Cell Biol (1999) 1.59
Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell (2005) 1.58
Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci U S A (1998) 1.58
A case of Down's syndrome with diffuse Lewy body disease and Alzheimer's disease. Neurology (1994) 1.55
Karyotype instability in Cryptococcus neoformans infection. J Clin Microbiol (1996) 1.53
Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother (1994) 1.53
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis (1996) 1.51
Melanisation of Cryptococcus neoformans in human brain tissue. Lancet (2000) 1.50
Ballooned neurons in select neurodegenerative diseases contain phosphorylated neurofilament epitopes. Acta Neuropathol (1986) 1.50
Serum therapy for Cryptococcal meningitis. Clin Infect Dis (1995) 1.50
Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol (1999) 1.48
Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans. Antimicrob Agents Chemother (1994) 1.48
Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration. Acta Neuropathol (1990) 1.48
Induction of nitric oxide synthase activity in human astrocytes by interleukin-1 beta and interferon-gamma. J Neuroimmunol (1993) 1.48